These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 9668372)
1. GM1 ganglioside for acute ischemic stroke. Trial design issues. Alter M Ann N Y Acad Sci; 1998 Jun; 845():391-401. PubMed ID: 9668372 [TBL] [Abstract][Full Text] [Related]
2. Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review. Zhang W; Krafft PR; Wang T; Zhang JH; Li L; Tang J Cell Transplant; 2019 Jun; 28(6):657-661. PubMed ID: 30666888 [TBL] [Abstract][Full Text] [Related]
4. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Methodological strategies and results of a double-blind, placebo-controlled trial of GM1 ganglioside. Grieco G; d'Hollosy M; Culliford AT; Jonas S Stroke; 1996 May; 27(5):858-74. PubMed ID: 8623106 [TBL] [Abstract][Full Text] [Related]
5. GM1 ganglioside treatment of focal ischemia: a dose-response and microdialysis study. Simon RP; Chen J; Graham SH J Pharmacol Exp Ther; 1993 Apr; 265(1):24-9. PubMed ID: 8474009 [TBL] [Abstract][Full Text] [Related]
8. GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy. Schneider JS; Roeltgen DP; Rothblat DS; Chapas-Crilly J; Seraydarian L; Rao J Neurology; 1995 Jun; 45(6):1149-54. PubMed ID: 7783880 [TBL] [Abstract][Full Text] [Related]
9. Monosialoganglioside GM1 in cerebral ischemia. Carolei A; Fieschi C; Bruno R; Toffano G Cerebrovasc Brain Metab Rev; 1991; 3(2):134-57. PubMed ID: 1854596 [TBL] [Abstract][Full Text] [Related]
10. Protection against Experimental Stroke by Ganglioside GM1 Is Associated with the Inhibition of Autophagy. Li L; Tian J; Long MK; Chen Y; Lu J; Zhou C; Wang T PLoS One; 2016; 11(1):e0144219. PubMed ID: 26751695 [TBL] [Abstract][Full Text] [Related]
13. GM1 ganglioside in the treatment of Parkinson's disease. Schneider JS Ann N Y Acad Sci; 1998 Jun; 845():363-73. PubMed ID: 9668369 [TBL] [Abstract][Full Text] [Related]
14. Effects of monosialoganglioside GM1 in experimental models of ischemic brain damage. Lipartiti M; Lazzaro A; Zanoni R; Bonvento G; Mazzari S Ital J Neurol Sci; 1991 Jun; 12(3 Suppl 11):11-3. PubMed ID: 1757215 [TBL] [Abstract][Full Text] [Related]
15. Early effects of GM1 in experimental cerebral focal ischemia in rabbits. Bo P; Marchioni E; Soragna D; Savoldi F Boll Soc Ital Biol Sper; 1993 Nov; 69(11):705-10. PubMed ID: 8060600 [TBL] [Abstract][Full Text] [Related]
17. GM1 ganglioside in Parkinson's disease: Results of a five year open study. Schneider JS; Sendek S; Daskalakis C; Cambi F J Neurol Sci; 2010 May; 292(1-2):45-51. PubMed ID: 20206941 [TBL] [Abstract][Full Text] [Related]
18. Growth factors and gangliosides as neuroprotective agents in excitotoxicity and ischemia. Hicks D; Heidinger V; Mohand-Said S; Sahel J; Dreyfus H Gen Pharmacol; 1998 Mar; 30(3):265-73. PubMed ID: 9510073 [TBL] [Abstract][Full Text] [Related]
19. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check. Goenka L; Uppugunduri Satyanarayana CR; S SK; George M Biomed Pharmacother; 2019 Jan; 109():2539-2547. PubMed ID: 30551514 [No Abstract] [Full Text] [Related]